Suggestions

Latest

Chemotherapy-Induced Peripheral Neuropathy Market

CIPN Market Size was around USD 1,500 million in 2023

21 January 2026
The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is emerging as a high-growth, high-value opportunity, fueled by a profound lack of approved therapies and a substantial unmet clinical need. As the global use of chemotherapy particularly neurotoxic agents continues to rise, the number
Geographic Atrophy Market
··

Geographic Atrophy Market Poised for Robust Growth

21 January 2026
The global Geographic Atrophy Market is expected to witness substantial growth over the forecast period from 2025 to 2034, fueled by a rising elderly population, increasing disease prevalence, growing demand for disease-modifying treatments, and the advancement of novel therapeutic approaches—particularly complement inhibitor
Sickle Cell Disease Market

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

20 January 2026
The Sickle Cell Disease (SCD) market is projected to experience remarkable growth through 2034, supported by increasing disease prevalence, improving diagnostic awareness, and rapid advancements in disease-modifying and gene-based therapies. According to DelveInsight, the market is expected to expand at a CAGR
Novartis Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren's Disease

Novartis Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease: First Targeted BAFF-R Blocking B-Cell Depleter Demonstrates Statistically Significant Disease Activity Reduction; Regulatory Submissions Planned Q1 2026

16 January 2026
NEPTUNUS-1 and NEPTUNUS-2 met primary endpoints with clinically meaningful improvements in ESSDAI and patient-reported outcomes across 779 globally enrolled patients; ianalumab positioned to become first approved targeted treatment for second most prevalent rheumatic autoimmune disease Novartis announced that the U.S. Food and
Optic Neuritis

FDA Grants Breakthrough Therapy Designation to Oculis’ PRIVOSEGTOR for Optic Neuritis: The First Neuroprotective Treatment in Rare Vision-Threatening Condition

12 January 2026
Swiss biotech company, Oculis Holding, achieves significant regulatory milestone following successful Phase 2 ACUITY trial results; global pivotal trials underway for first-in-class therapy addressing critical unmet medical need Oculis Holding AG announced that the Food and Drug Administration (FDA) has granted Breakthrough
1 … 42 43 44 45 46 … 48

    Banner

    Newsletter